From a patient's point of view

P1.1

Japanese Practical Guidance on the effective transition of adolescents with Sjögren’s Disease

P1.2

Traditional Chinese Medicine for Sjögren's syndrome: A national survey of attitudes and perceptions among Chinese patients and rheumatologists

P1.3

withdrawn

P1.4

Living with Sjögren's: Patient Perspectives

P1.5

The Importance of patient engagement during the development of new medicine for the treatment of Sjögren’s Disease

P1.6

Current areas of unmet need, the greater extent of Sjögren's systemic disease symptoms, mental health and perceptions towards complementary and alternative medicine (CAM) identified through a patient co-designed study.

P1.7

Networks of fatigue, pain and biopsychosocial factors in people with Sjögren's disease.

P1.8

Gathering all stakeholders in its 1st Conference: the successful bet of Sjögren Europe

P1.9

Myths vs Realities: An honest feedback from the scientific community on collaboration with patients partners in the NECESSITY project

Glands and imaging

P1.10

Updated data on safety and patient tolerability of US-guided core needle biopsy of major salivary glands in patients affected by Sjögren’s syndrome at increased risk for lymphoma

P1.11

Long-term prognosis of patients with Sjögren’s disease diagnosed in childhood who have reached adulthood, based on a questionnaire survey

P1.12

Five years’ experience with Saliclick in a single tertiary centre: an effective and safe device for minimal invasive salivary gland biopsy in suspected Sjögren's disease

P1.13

Sequential minor salivary gland biopsy in patients with Sjogren’s disease reveal differences in focus score

P1.14

The role of minor salivary gland histology in patients with Sjögren's Syndrome: a multcicentric cross-sectional observational study

P1.15

Lacrimal gland ultrasound demonstrates good interobserver reliability

P1.16

Single-cell transcriptomics offers New Insights into SjD Pathogenesis in the Salivary Gland

P1.17

Major Salivary Gland Ultrasound And Elastography For Assessment Of Disease Activity In Patients Of Primary Sjögren’s Syndrome

Pathogenetic aspects

P1.18

withdrawn

P1.19

Quantitative Analysis of Bcl-2-Gene-Protein Expression in Salivary Glands of Xerostomic Patients

P1.20

Sjögren’s Syndrome Autoantigen TRIM21/Ro52 is Released During Lytic Cell Death and Facilitates Immune Complex Formation

P1.21

BDCA2+ dendritic cells and a type I interferon (IFN) signature in biopsy positive minor salivary glands and a type I IFN signature in blood are increased in primary Sjogren’s disease as compared to non-Sjogren’s sicca

P1.22

A novel function of IL-17 in driving hyposalivation during the development of Sjögren's Syndrome: implications for therapeutic intervention

P1.23

The role of T follicular helper cells in the pathogenesis of Sjögren's Syndrome

P1.24

Sjögren Syndrome and non-Sjögren Syndrome Dry Eye Patients Have Similar Transcripts Involved Immune Pathways in the Conjunctiva.

P1.25

Investigating MMP7, MMP9 and TIMP1 mRNA expression patterns in minor salivary glands from patients with primary Sjögren’s syndrome (pSS) using RNAscope®

P1.26

Evaluation of T-regulatory cell function in mice colonized with gut microbes from either Sjögren’s disease or healthy control human patients

P1.27

Autoreactive B cells in the peripheral blood of patients with Sjögren’s disease

P1.28

Mitochondrial Dysfunction and Fatigue in Sjögren’s Disease

P1.29

Withdrawn

P1.30

Revisiting the Functional Circuit in Sjogen's Disease

P1.31

Systemic ocular surface involvements in the development of Sjögren's syndrome associated dry eye in the IL-14α transgenic mouse

P1.32

How a parotid biopsy can lead to increased tear production: Lidocaine-induced tear production in Sjogren's disease may provide novel therapeutic options

P1.33

Altered mitochondrial morphology in salivary epithelial cells of Sjögren’s syndrome patients is associated with mitochondrial DNA release and a pro-inflammatory response.

P1.34

Spatial imaging of the salivary gland tissue microenvironment in Sjögren’s disease using Imaging Mass Cytometry™

P1.35

Giantin mislocalization affects mucin sulfation in labial salivary glands of Sjögren’s syndrome patients.

P1.36

Anti-M3R ECL Antibody Induction by Immunization with 4-Hydroxy-2-nonenal Modified Ro60/Unmodified Ro60 and generation of Anti-Ro60 by M3R Peptide Immunization

P1.37

Differential Induction of Anti-Muscarinic Type-3-Receptor Antibodies by Immunization with 4-Hydroxy-2-nonenal-Modified Ro60 in BALB/C Mice

P1.38

Dynamic Emergence of Autoimmunity and Sialadenitis in Aging Mice Provides a Novel Gateway to Deciphering Sjögren's Disease

P1.39

TLR2 promotes cytotoxicity and inflammatory response of CD8+T cells by activating mitophagy in primary Sjogren's syndrome

Trials and tools

P1.40

An update on the progress of NECESSITY project

P1.41

Clinical practice guidelines for the treatment of primary Sjögren’s syndrome by off-label drug use in China (The edition 2023)

P1.42

Novel autoantibodies help diagnose anti-SSA antibody negative Sjögren’s disease and predict abnormal labial salivary gland pathology

P1.43

Real-world Effectiveness and Safety of tofacitinib in primary Sjögren’s syndrome : A Single-centre Study

P1.44

A Non-Invasive Model for Diagnosis of Primary Sjogren’s Syndrome Based on Salivary Biomarkers, Serum Autoantibodies, and Schirmer's Test

P1.45

Effect of Paeoniae Rubra Radix and Sargentodoxa cuneata on increasing IL-2 level to regulate the Tfh / Treg balance in Sjögren's syndrome

P1.46

Using cutting-edge proteomics to explore the therapeutic role of Shaoteng Decoction（STD） in Sjögren's syndrome

P1.47

Immune Synergy of IL-2 and Rapamycin：A Novel Approach in Treating Sjögren's Syndrome

P1.48

Long term clinical benefits in patients presenting with distal renal tubular acidosis (dRTA) treated with Sibnayal®, an oral twice-daily fixed and prolonged-release combination of potassium bicarbonate and potassium citrate: 6-year results

P1.49

Insulin eye drop for treatment of dry eye in Sjögren’s Disease

P1.50

Neutralizing FLT3L with the Monoclonal Antibody AMG 329 for the Treatment of Various Inflammatory Diseases Reduces Levels of Dendritic Cells and Monocytes In Vivo

P1.51

Efficacy of long-term rituximab therapy in the glandular manifestations of Sjogren's disease

P1.52

Dazodalibep, a CD40L Antagonist, in a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial of Subjects with Sjögren’s Disease having Unacceptable Symptomatic Burden but Limited Extraglandular Organ Involvement

P1.53

CD40L Inhibition with Dazodalibep Rapidly Reduces Blood Biomarkers of T and B Cell Costimulation in Subjects with Sjögren’s Disease Having High Disease Activity or High Symptom Burden

P1.54

Systemic disease activity measured with ESSDAI varies largely over five years in a prospective, longitudinal cohort of patients with Sjögren’s disease

P1.55

A survey of italian specialists in Obstetrics and Gynecology regarding clinical practice for vaginal dryness and Sjögren's syndrome

P1.56

Acupuncture therapy for adults with Primary Sjogren Syndrome: A qualitative research

P1.57

Efficacy of combination therapy with BTK inhibitors and immunochemotherapy for extranodal marginal zone lymphoma associated with Sjögren's syndrome

Extra-glandular involvement

P1.58

The association between STAT4 Polymorphism and Pulmonary Arterial Hypertension in Chinese patients with Primary Sjogren’s Syndrome

P1.59

Androgen and glucocorticoid dysregulation in Sjogren’s disease and non-Sjogren's sicca.

P1.60

Prevalence and significance of nailfold capillaroscopy abnormalities in primary Sjogren’s syndrome compared to primary Raynaud phenomenon

P1.61

Neurological Manifestations of Sjögren’s Disease: the relevance of clinical questionnaires and biomarkers

P1.62

A Novel TRIM21(E38G) Mutation Affects IFN and Cytokine Driving a Sjögren’s-like Phenotype

P1.63

Successful treatment of a rare case of coronary vasculitis associated to diffuse large B-cell lymphoma in a patient affected by primary Sjögren’s syndrome

P1.64

Increased risk of dementia in patients with primary Sjogren’s syndrome: a nationwide population-based cohort study

P1.65

Interstitial lung disease, associated with Sjögren's disease: clinical characteristics, efficacy of rituximab therapy, lymphoma association

P1.66

Lymphocytic Interstitial Pneumonia is associated with a peculiar phenotype of Primary Sjögren’s Syndrome

P1.67

Assessment of cognitive disorders in patients with Sjögren's disease in a Brazilian’s hospital reference center

P1.68

Seronegative vs. Seropositive Sjögren's Syndrome: A Comprehensive Clinical Study in a Chinese Population

P1.69

Bone microarchitecture impairment in patients with Sjögren’s disease is associated with damage index

P1.70

Evaluation of Bone Microarchitecture and Physical Activity in Patients with Sjögren's Disease

P1.71

The risk of heart diseases in offspring born to mothers with primary Sjögren's syndrome: a multi-center retrospective study

P1.72

Rituximab in cryoglobulinemic vasculitis secondary to primary Sjögren’s Syndrome: the earlier the better. A single-center retrospective cohort study

Classification and stratification

P1.73

Identification of a saliva exosomal-rna signature for Sjögren's Syndrome

P1.74

Characterization of patients with Sjögren’s disease and elevated serum IgA and IgG levels

P1.75

Questionnaire Survey for the Status of standardized diagnosis for Sjögren's syndrome in China

P1.76

The relationship between smoking status and Sjögren’s Disease diagnosis and disease activity: results of a single centre cohort study

P1.77

Cardio- and cerebrovascular events between Hungarian Sjögren’s syndrome patients

P1.78

Increased risk of adverse gestational outcomes in pregnant women with primary Sjögren's syndrome

P1.79

Impact of Disease Duration on systemic clinical profile in Sjogren’s Syndrome

P1.80

Two pediatric cases accidentally diagnosed Sjögren’s disease: we should always think about SD

P1.81

Anti-Ku positivity in primary Sjögren’s disease is associated with a more active disease.

P1.82

The impact of the age in major relapses of cryoglobulinemic vasculitis related to primary Sjögren’s syndrome

P1.83

Clinical and immunological characteristics of elderly-onset primary Sjögren's syndrome

P1.84

Clinicopathologic and immunophenotypic study of the salivary gland involvement in pediatric Sjögren's Disease: The quest for childhood-adapted criteria and long-term follow up

P1.85

Identification of distinct phenotypes of Sjögren disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts.